Verastem, Inc., VSTM, a clinical-stage biopharmaceutical
company focused on discovering and developing drugs to treat cancer by
the targeted killing of cancer stem cells, announced the publication of
data for VS-5584 in Molecular Cancer Therapeutics.
VS-5584 is a potent and selective inhibitor of the PI3K/mTOR pathway.
Previous research has described a central role of this pathway in cancer
stem cells. The current study details the biochemical properties and
preclinical effects of this compound in multiple human tumor models.
“The PI3K/mTOR signaling pathway appears critical for the survival and
self-renewal of cancer stem cells,” said Jonathan Pachter, Ph.D.,
Verastem Vice President and Head of Research. “We have established a
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in